Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$31.95M, compared with -$29.63M a year earlier. Trailing-twelve-month operating income was -$110.32M.

Context

  • Operating income amounted to 273.1% of revenue in FY2025, up 93.2 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 1 analysts of -$63.21M (+41.5%) for the fiscal year ending Dec 2026, a step up from the -3.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$31.95M-27.9% QoQ
Last fiscal yearDec 2025
-$108M-3.9% YoY
LTMMar 2026
-$110.32M-34.4% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.8%+23.2%+31.0 pp
1 year-3.9%+41.5%+45.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(108M) USD
Year-over-year change
-3.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -34.4% is the lowest of 11, against a peer median of +13.0%.
  • Operating income amounts to 319.2% of revenue for SGMO, versus a peer median of 1093.0%.
SGMO Competitors
Operating Income for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CDXSCodexis, Inc.LTM Mar 2026-$25.89M USD+61.4%—33.2%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$34.64M USD+32.5%—1093.0%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-$37.23M USD+7.9%—1258.6%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-$41.17M USD+29.7%—2112.4%
IPHAInnate Pharma S.A.FY2025-€53.43M EUR-3.6%—1916.9%
OABIOmniAb, Inc.LTM Mar 2026-$57.93M USD+18.2%—200.3%
MOLNMolecular Partners AGLTM Mar 2026-CHF 61.98M CHF+2.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$65.46M USD-25.5%—3669.4%
IVVDInvivyd, Inc.LTM Mar 2026-$81.77M USD+44.6%—146.4%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$110.32M USD-34.4%—319.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$113.84M USD+2.3%—326.6%
Peer median (excluding SGMO) —+13.0%—1093.0%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.